



**Multiple Myeloma: A retrospective Analysis
of the Patients Treated at Ain Shams
University Clinical Oncology Department
with a Review of the Literature**

Thesis

*Submitted for Parital Fulfillment of Master Degree in
Oncology and Nuclear Medicine*

By

Moushira Esmail Hassan El-Sakka

M.B.B.CH

Under Supervision of

Dr. Khaled Abdel Karim

*Professor of Clinical Oncology and Nuclear Medicine
Faculty of Medicine - Ain Shams University*

Dr. Mohamed Yassin Mostafa

*Assistant Professor of Clinical Oncology and Nuclear Medicine
Faculty of Medicine - Ain Shams University*

Dr. Khaled Kamal El-Din Elghoniemy

*Lecturer of Clinical Oncology and Nuclear Medicine
Faculty of Medicine - Ain Shams University*

Faculty of Medicine
Ain Shams University
2018

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لَسْبَدَانُكَ لَا نَعْلَمُ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Dr. Khaled Abdel Karim**, Professor of Clinical Oncology and Nuclear Medicine Faculty of Medicine - Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Dr. Mohamed Yassin Mostafa**, Assistant Professor of Clinical Oncology and Nuclear Medicine Faculty of Medicine - Ain Shams University, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Khaled Kamal El-Din Elghoniemy**, Lecturer of Clinical Oncology and Nuclear Medicine Faculty of Medicine - Ain Shams University, for his great help, active participation and guidance.*

Moushira Esmail

List of Contents

Title	Page No.
List of Tables	5
List of Figures	7
List of Abbreviations	9
Abstract	12
Introduction	1
Aim of the Work.....	14
Review of Literature	
▪ Multiple Myeloma Incidence and Epidemiology	15
▪ Pathogenesis of Multiple Myeloma	18
▪ Diagnosis	25
▪ Management.....	47
Patients and Methods	71
Results	73
Discussion	101
Summary & Conclusion	108
Recommendations	110
References	111
Arabic Summary	—

List of Tables

Table No.	Title	Page No.
Table (1):	Relevant laboratory tests in myeloma.....	32
Table (2):	Conventional radiographic status in multiple myeloma.....	34
Table (3):	International staging system of multiple myeloma.....	45
Table (4):	Standard risk factors for MM and the revised ISS.	45
Table (5):	International Myeloma Working Group Diagnostic Criteria for Multiple Myeloma and Related Plasma Cell Disorders.....	47
Table (6):	Criteria for High Risk Smoldering Multiple Myeloma.....	49
Table (7):	Major Treatment Regimens in Multiple Myeloma.	50
Table (8):	Distribution of the studied cases according to demographic and clinical data	73
Table (9):	Sex.....	74
Table (10):	Other recorded Comorbidities.	75
Table (11):	Other recorded Comorbidities.	75
Table (12):	Presenting symptoms.	76
Table (13):	Distribution of the studied cases according to diagnostic investigations.....	77
Table (14):	Distribution of the studied cases according to Stage at time of presentation.....	78
Table (15):	Distribution of the studied cases according to 1 st line Treatment	79
Table (16):	Number of cycles.....	80
Table (17):	Response to first line.	81
Table (18):	Distribution of the studied cases according to 2 nd line Treatment	82
Table (19):	Number of cycles.....	83
Table (20):	Response to second line.....	84

List of Tables Cont...

Table No.	Title	Page No.
Table (21):	Distribution of the studied cases according to Toxicities	85
Table (22):	Distribution of the studied cases according to Clinical Response	87
Table (23):	Distribution of the studied cases according to Overall survival at time of data collection	88
Table (24):	Overall Survival.....	89
Table (25):	Progression free survival.....	90
Table (26):	Kaplan-Meier survival curve for Overall Survival.....	90
Table (27):	Kaplan-Meier survival curve for progression free survival.....	91
Table (28):	Serum Calcium.....	93
Table (29):	Serum Albumin.....	94
Table (30):	Beta2- microglobulin.....	95
Table (31):	Skeletal survey.....	96
Table (32):	Stage at time of presentation.....	97
Table (33):	Number of Cycles of 1 st line treatment.....	98
Table (34):	2 nd line Treatment.....	99
Table (35):	Autologous Stem Cell Transplantation.	100

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Tumour microenvironment.	22
Figure (2):	Thoracic spine x-ray demonstrating multiple wedge compression insufficiency fractures typical of myeloma.	27
Figure (3):	X-ray of an osseous myeloma lesion.....	34
Figure (4):	Computed tomography of an osseous myeloma lesion.....	36
Figure (5):	Computed tomography of an osseous myeloma lesion.....	37
Figure (6):	Whole-body magnetic resonance imaging of an osseous myeloma lesion	38
Figure (7):	a-d) Positron emission tomography of an osseous myeloma lesion	40
Figure (8):	Positron emission tomography/computed tomography of extraosseous myeloma lesions.....	40
Figure (9):	Approach to the treatment of newly diagnosed multiple myeloma in transplant eligible and transplant ineligible patients	52
Figure (10):	Suggested options for the treatment of relapsed multiple myeloma in first relapse (A) and second or higher relapse (B).....	61
Figure (11):	A,B) Positron emission tomography for therapy monitoring	70
Figure (12):	Age.	73
Figure (13):	Sex.	74
Figure (14):	Comorbidities.	75
Figure (15):	Presenting symptoms.	76
Figure (16):	Stage at time of presentation.	78
Figure (17):	Regimen.....	79
Figure (18):	Number of cycles.	80
Figure (19):	Response to first line.	81
Figure (20):	Regimen.....	82

List of Figures Cont...

Fig. No.	Title	Page No.
Figure (21):	Number of cycles.	83
Figure (22):	Response to second line.....	84
Figure (23):	Toxicities of treatment and grading.....	86
Figure (24):	Clinical response.	87
Figure (25):	Overall survival at time of data collection.	88
Figure (26):	Progression free survival.....	89
Figure (27):	Correlation between Serum Calcium and OS,PFS.	92
Figure (28):	Correlation between Serum Albumin and OS,PFS.	93
Figure (29):	Correlation between beta2- microglobulin and OS,PFS.	94
Figure (30):	Correlation between skeletal survey and OS,PFS.	95
Figure (31):	Correlation between stage of disease and OS, PFS.	96
Figure (32):	Correlation between number of cycles in 1 st line treatment and OS,PFS.	97
Figure (33):	Correlation between 2 nd line treatment and OS,PFS.	98
Figure (34):	Correlation between ASCT and OS,PFS.....	99

List of Abbreviations

Abb.	Full term
ASCT.....	Autologous stem cell transplantation
BMA.....	Bone marrow aspirate
BMB.....	Bone marrow biopsy
BMPCs.....	Bone marrow plasma cells
CA	Chromosomal abnormalities
CAMDR	Cell adhesion-mediated drug resistance
CBC.....	Complete blood count
CT	Computed tomography
CXCR	CXC-chemokine receptor type 4
DCE	Dynamic contrast-enhanced
DFCI.....	Dana-Farber Cancer Institute
DWI.....	Diffusion-weighted imaging
FDA.....	Food and Drug Administration
FLC	Free light chain
HLC	Heavy/light chain
iFISH	interphase FISH
IFM.....	Intergroupe Francophone du Myelome
IMWG	International Myeloma Working Group
IRd	Ixazomib, lenalidomide, dexamethasone
ISS	International Staging System
KRD	Carfilzomib (Kyprolis)- Lenalidomide- Dexamethasone
LDH	Lactate dehydrogenase
MGUS.....	Monoclonal gammopathy of undetermined significance
miRNA.....	microRNA
MM.....	Multiple myeloma
MP.....	Melphalan, prednisone

List of Abbreviations Cont..

Abb.	Full term
MPT	Melphalan, prednisone, thalidomide
MRI	Magnetic resonance imaging
NCCN	National Comprehensive Cancer Network
OS	Overall survival
PET	Positron emission tomography
PFS	Progression free survival
RANKL	Receptor activator of nuclear factor- κ B ligand
Rd	Lenalidomide plus dexamethasone
R-ISS	Revised ISS
SLAMF7	Signaling lymphocytic activation molecule F7
SMM	Smouldering MM
SUV	Standardized uptake value
SWOG	Southwest Oncology Group
TTP	Time to progression
VCD	Bortezomib (Velcade)- cyclophosphamide- dexamethasone
VEGFA	Vascular endothelial growth factor A
VRD	Bortezomib (Velcade)- lenalidomide (Revlimid)- dexamethasone
VTD	Bortezomib (Velcade)- Thalidomide- Dexamethasone
ECOG	Eastern Cooperative Oncology Group
G-CSF	Granulocyte stimulating factor
MDS	Myelodysplastic syndrome
VMP	Bortezomib (Velcade) – Melphalan – Prednisone
VMPT	Bortezomib (Velcade) – Melphalan – Prednisone Thalidomide

List of Abbreviations Cont..

Abb.	Full term
TRM	Transplantation-related mortality
GVHD	Graft-versus-host disease
MRC	Medical research council
BIPN	Bortezomib _induced Peripheral neuropathy
SDS	Salmon-Durie staging system
SD	Stationary disease
PR	Partial response
CR	Complete response
PD	Progressive disease
CTCAE.....	Common Terminology Criteria for Adverse Effects
¹⁸ F-FDG	¹⁸ F-fluorodeoxyglucose
CRP	C-reactive protein
LDH	Lactate dehydrogenase
ISS	The International Staging System
MDEs	Myeloma-defining events
TD	Thalidomide-Dexamethasone
Pom/Dex	Pomalidomide-Dexamethasone
VD	Bortezomib-Dex
VMP	Bortezomib-Melphalan-Prednisone
CyBorD	Bortezomib- Cyclophosphamide- Dexamethasone
CCyD.....	Carfilzomib- Cyclophosphamide- Dexamethasone

Abstract

Multiple Myeloma: Aretrospective analysis of the patients treated at Ain Shams University Clinical oncology department with a review of the literature.

Purpose/Objective: This study aims at analysis the epidemiological data of the patients treated from multiple myeloma at Ain Shams University together with reviewing the different lines of management according to recent recommendations.

Patients and methods: This retrospective analyses of 62 patients with multiple myeloma data recorded at their files with follow up and reviews of the recent advances in the management of multiple myeloma.

Results: among 62 patients involved in the present study we found that 96.8% of patients showing clinical improvement after treatment on other hand only 3.2% deteriorated, 61.35 of patients were alive,9.7% died and 29% lost follow up, the mean time to DFS was 22.55 months, mean OS was 63.2 months with 87.8% of patients survived at the end of the study,as regard mean PFS was 54.9 months with PFS at end of study was 74.9% of patients, there was insignificant differences between OS and demographic data,laboratory studies, there was insignificant differences between PFS and demographic data,laboratory studies.

Conclusion: Multiple myeloma (MM) is a heterogeneous hematologic malignancy involving the proliferation of plasma cells derived by different genetic events contributing to the development, progression, and prognosis of this disease.

Key words: Multiple myeloma –Kahler’s disease – Egyptian patients – prognostic factors.

INTRODUCTION

Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone marrow leading to bone destruction and marrow failure (*Siegel et al., 2017*).

Most cases of multiple myeloma also feature the production of a para protein (an abnormal antibody) which can cause kidney problems. Bone lesions and hypercalcemia are also often encountered (*Dimopoulos et al., 2011*).

Multiple myeloma accounts for about 1.8% of all cancers and slightly over 17% of all the hematologic malignancies in the United States. Myeloma is most frequently diagnosed among people aged from 65 to 74 years with median age 69 years. About 30,280 new myeloma cases have been estimated in the United States in 2017 with an estimated 12,590 deaths (*Siegel et al., 2017*).

It is more common in men and for unknown reasons, is twice as common in African Americans as it is in White Americans. With conventional treatment, median survival is 3–4 years, which may be extended to 5–7 years or longer with advanced treatments (*Ocio et al., 2008*).

AIM OF THE WORK

This study aims at analysing the epidemiological data of the patients treated from multiple myeloma at Ain Shams University together with reviewing the different lines of management according to recent recommendations.

Chapter 1

MULTIPLE MYELOMA INCIDENCE AND EPIDEMIOLOGY

Almost all patients with Multiple Myeloma (MM) evolve from an asymptomatic pre-malignant stage termed monoclonal gammopathy of undetermined significance (MGUS). MGUS progresses to MM at a rate of 1% per year. In some patients, an intermediate asymptomatic but more advanced pre-malignant stage termed smouldering (or indolent) multiple myeloma (SMM) can be recognised. SMM progresses to myeloma at a rate of 10% per year over the first 5 years following diagnosis, 3% per year over the following 5 years, and 1.5% per year thereafter (*Rajkumar et al., 2014*).

Multiple myeloma accounts for approximately 1.8% of all cancers and slightly >15% of hematologic malignancies in the United States. Myeloma is most frequently diagnosed among people aged 65 to 74 years, with the median age being 69 years. In 2016, the American Cancer Society estimated that 30,330 new cancer cases occurred in the United States, with an estimated 12,650 deaths (*Siegel et al., 2017*).

Egyptian data from national population-based cancer registry, MM represented 0.53% of cancers in males and 0.34% of cancers in females at period from (2008-2011) with peak age of diagnosis from 60 to 65 years in males and from 70 to 75